Back

Safety and efficacy of macitentan and riociguat upfront combination therapy in patients with idiopathic pulmonary arterial hypertension at intermediate risk.

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary arterial hypertension therapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Michele D'Alto

AORN Ospedali dei Colli - Monaldi Hospital, Naples (Italy)

4 More presentations in this session

Presentation thumbnail
A real-world study on selexipag for pulmonary arterial hypertension: a single-center retrospective study
Doctor R. Asano (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Could we maintain the initial efficacy of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : Insights from a single-centre study
Associate Professor H. Tokgoz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of selexipag based triple combination targeted drug therapy in chinese patients with pulmonary arterial hypertension
Doctor X. Cui (Jinan, CN)
Abstract Slides Video
Presentation thumbnail
Switching sildenafil to riociguat in chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty - the S2R study
Doctor T. Kam (Shatin, HK)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary arterial hypertension therapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Molecular approaches to the treatment of pulmonary hypertension
thumbnail
Congress Session
Phenotyping and risk stratification in pulmonary arterial hypertension
thumbnail
Congress Session
Phenotypes and management strategies in pulmonary hypertension

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources